ARIS vs CC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ARIS exhibits a stable financial health profile with a Piotroski F-Score of 4/9 and a strong balance sheet characterized by low debt/equity (0.36). While the company is delivering explosive triple-digit growth in revenue (104.2%) and earnings (121.7%), the stock is significantly overvalued, trading at $18.76 against a Graham Number of $8.06 and an Intrinsic Value of $12.09. The combination of a bearish technical trend (0/100) and a high P/E ratio suggests that the market has already priced in much of the future growth, creating a high-risk entry point despite strong fundamentals.
The Chemours Company exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and an alarming Debt/Equity ratio of 17.51. While the stock has seen a massive 1-year price surge of 119.6%, this momentum is decoupled from fundamentals, as evidenced by a negative ROE of -93.80% and shrinking revenue. The dividend is unsustainable with a payout ratio of 555.56%, and the current price of $26.61 already exceeds the analyst target price of $21.67. Overall, the company appears to be in a high-risk state with significant solvency concerns.
Compare Another Pair
Related Comparisons
ARIS vs CC: Head-to-Head Comparison
This page compares Aris Mining Corporation (ARIS) and The Chemours Company (CC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.